AGM/EGMJun 9, 2026, 04:12 PM
Arcutis Stockholders Approve Directors, Auditor, & Comp Plan
AI Summary
Arcutis Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where all three proposals were approved. Stockholders elected three Class III directors, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and approved the compensation of named executive officers on a non-binding advisory basis. Additionally, the Board approved revisions to the Non-Employee Director Compensation Program to attract and retain qualified directors, effective as of the Annual Meeting.
Key Highlights
- Arcutis Biotherapeutics held its 2026 Annual Meeting of Stockholders on June 5, 2026.
- All three proposals submitted to stockholders were approved.
- Patrick J. Heron, Neha Krishnamohan, and Todd Franklin Watanabe were elected as Class III directors.
- Ernst & Young LLP was ratified as the independent auditor for fiscal year 2026 with 107,867,442 votes for.
- Named executive officer compensation was approved on a non-binding advisory basis with 88,728,269 votes for.
- The Board approved revisions to the Non-Employee Director Compensation Program, effective from the Annual Meeting.
- 125,073,249 shares were outstanding and entitled to vote as of the record date.
Price Impact
More from ARQT